Home / Health / PSA Screening Rates Decline After USPSTF Says ‘No’

PSA Screening Rates Decline After USPSTF Says ‘No’

Prostate cancer screening and a occurrence of early-stage illness have declined given a U.S. Preventive Services Task Force (USPSTF) endorsed opposite slight screening PSA tests, American Cancer Society (ACS) investigators reported.

The rate of PSA screening declined by roughly 20% from 2010 to 2013 after augmenting from 2005 to 2008. Screening patterns were identical among men, ages 50 to 74 and those who were older.

The occurrence of early-stage prostate cancer augmenting rather from 2005 to 2008 and afterwards declined by 23% by a finish of 2012, about 6 months after USPSTF announced a recommendation. Most of a diminution in cancer occurrence occurred during 2011 and 2012, Ahmedin Jemal, DVM, PhD, of a ACS, and colleagues reported in JAMA. A causal attribute is probably a certainty.

“The diminution in occurrence for early-stage prostate cancer occurred within a year after a recover of a USPSTF breeze recommendation opposite screening in Oct 2011, that was widely debated in a media and systematic literature,” a authors noted. “Similar changes in occurrence of cancer following new screening recommendations, changes in payment policies, or newsworthy publications have been formerly remarkable for other cancers.”

“Alternative explanations for a estimable diminution in occurrence between 2011 and 2012,” they added. “There are no famous clever risk factors for prostate cancer, for that temporal changes are expected to impact incidence, quite for early-stage disease.”

A investigate minute published in a same emanate of JAMA described a diminution in prostate cancer screening from 36% of authorised organisation in 2001 to 31% in 2013, a statistically poignant 21% dump in a contingency ratio (OR). In contrariety to a ACS study, a investigate showed that showed incomparable declines among younger men, Jesse D. Sammon, DO, of Henry Ford Health System in Detroit, and colleagues reported.

Controversy Will Persist

Acknowledging stipulations of a retrospective databases used for a analyses, a author of an concomitant editorial pronounced a findings, total with those of a European Randomized Study of Screening for Prostate Cancer (ERSPC), advise that as many as 1,241 organisation competence die of prostate cancer as a outcome of not being screened.

“Some assumptions competence not be totally valid, though this guess expected still provides a severe estimation of a series of prostate cancer deaths that will be compared to this 1-year diminution in PSA screening rates and a compared diminution in illness incidence,” wrote David Penson, MD, MPH, of Vanderbilt University in Nashville. “This guess competence even be rather regressive given other investigators have suggested that a NND [number indispensable to detect to forestall one prostate cancer death] compared with a ERSPC will diminution serve as a hearing accrues longer follow-up.”

“Although it is essential to acknowledge that these projections are severe approximations, they will prove a intensity for some grade of mistreat in a form of additional mankind due to prostate cancer compared with a diminution in PSA screening that has occurred following a USPSTF recommendation,” Penson added.

Penson also concurred that a diminution in PSA contrast rates authorised many organisation with phlegmatic illness to equivocate a “considerable inauspicious effects of medicine or radiation.” The usually approach to solve a stream debate over PSA screening tests is “to put aside a tongue and try to rise improved ways to shade for this common malignancy,” he concluded.

Despite anticipating that a advantages of screening tests do not transcend a intensity harms, a USPSTF recognizes “some organisation will continue to ask screening and some doctors will continue to offer it,” charge force member Douglas Owens, MD, of Stanford University in Stanford, Calif., pronounced in an email. “Patients requesting screening should be supposing with a event to make sensitive choices to be screened that simulate their values about specific advantages and harms.”

Noting that a mankind advantage of screening competence not seem for 7 to 10 years after conflict of screening, Owens pronounced USPSTF agrees with Jemal’s organisation that “additional investigate is indispensable to establish if a diminution in a occurrence of early-stage prostate cancer is compared with trends in mortality.”

When a charge force endorsed opposite slight screening PSA tests, a American Academy of Family Physicians (AAFP) followed fit with a possess recommendation opposite slight screening. As a result, a AAFP deliberate a information good news.

“We’re gratified to see that a rate of PSA screening has declined,” AAFP boss Wanda Filer, MD, pronounced around email. “The information uncover that physicians are profitable courtesy to evidence-based recommendations and responding accordingly.”

Background and Results

The USPSTF has done dual recommendations opposite slight PSA screening tests. In 2008, a charge force endorsed opposite slight screening in organisation 75 or older, and prostate cancer occurrence has declined almost in that age organisation given then, Jemal and colleagues noted. In late 2011, a USPSTF endorsed opposite slight screening in all men, irrespective of age. The impact of a latter recommendation on prostate cancer occurrence has remained unclear. The recommendation was finalized in May 2012.

To inspect temporal associations between a USPSTF recommendation and trends in PSA contrast and prostate cancer incidence, investigators during a ACS reviewed information from a NCI Surveillance, Epidemiology, and End Results (SEER) module and identified organisation with newly diagnosed theatre we prostate cancer from 2005 by 2012. They also analyzed self-reported PSA contrast information supposing by organisation 50 or comparison for a National Health Interview Survey (NHIS) for 2005, 2008, 2010, and 2013 (n=18,385).

Prostate cancer occurrence for 446,009 organisation 50 and comparison in a SEER registries augmenting from 534.9/100,000 in 2005 to 540.8/100,000 in 2008, followed by a diminution to 505.0/100,000 in 2010, 416.2/100,000 in 2012. The largest diminution occurred during 2011 and 2012, when a occurrence creased from 498.3/100,000 to 416.2/100,000. In comprehensive terms, a series of organisation national with newly diagnosed early prostate cancer decreased from 213,562 in 2011 to 180,043 in 2012.

The suit of organisation 50 or comparison stating a screening PSA examination within a past 12 months augmenting from 36.9% in 2005 to 40.6% in 2008, afterwards decreased to 37.8% in 2010 and 30.8% in 2013. The OR for screening was 1.10 during 2005 to 2008 contra 0.82 for 2010 to 2013.

Sammon’s organisation analyzed NHIS information for 2000, 2005, 2010, and 2013 (n=20,757) to review rates of screening PSA tests before and after a USPSTF 2012 recommendation. The self-reported screening rate augmenting from 34% during 2005 to 2008 to 36% in 2008 and afterwards decreased to 31% in 2010. A pooled investigate comparing 2013 and 2010 yielded an OR of 0.79.

The rate of PSA screening decreased significantly by 22% (OR 0.78, 95% CI 0.70-0.88) in organisation younger than 75, though a 15% diminution among comparison organisation did not grasp statistical stress (OR 0.85, 95% CI 0.66-1.10). The biggest drops occurred among organisation 50 to 54 (23% to 18%, OR 0.71, 95% CI 0.56-0.91) and 60 to 64 (45% to 35%, OR 0.69, 95% CI 0.54-0.89).

Elusive Balance

The idea of distinguished a change between mistreat and advantage stays elusive, and a debate about screening PSA tests will insist until a resolution emerges, pronounced urologist Herbert Lepor, MD, of NYU Langone Medical Center in New York City.

“We need to shade smarter,” Lepor pronounced by email. “There are tests — like a 4K[score] that detects many intermediate-risk illness and decreases a risk of detecting low-risk disease.” Lepor recently authored a review essay on a use of a 4Kscore system.

Offering a clinical version to illustrate a stream situation, Lepor said, “I saw a male a week ago who 5 years ago had a rather towering PSA and inaugurated no intervention. Because of a screening controversy, he didn’t do anything some-more until a few weeks ago when a follow-up PSA was 22 [ng/mL]. On digital rectal exam, he had cancer that had widespread good over a prostate locally. He will expected die of his illness that was expected detectable and curable 5 years ago.”

“So, is a diminution in screening good or bad?” Lepor asked. “I have large concerns that we will see augmenting mortality.”

The investigate by Jemal’s organisation was saved by a Intramural Research Department of a ACS.

Jemal and co-authors disclosed no applicable relations with industry.

Sammon and co-authors disclosed no applicable relations with industry.

Penson disclosed no applicable relations with industry.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco

Article source: http://www.medpagetoday.com/HematologyOncology/ProstateCancer/54778

Scroll To Top